Member Info for jint

Hi bobfraeberks,

Agree, Brands find underscores SNG’s strategy.

Trust all is well, hope to see you again at the next AGM.

Hopefully we’ll have the trial execution and positive news to discuss over a pint or two.

Thanks Brand, excellent find!

Take a look at the ‘Description’ in the Casanova patent application:

‘This invention was made with government support under numbers R01AI088364, UL1TR001866, UM1HG006504 and U24HG008956 awarded by the National Institutes of Health. The government has certain rights in the invention.’

Big backers for this assay test and Synairgen are in the mix to use it for their Phase2 trials.

TommyD_19

I can confirm during the AGM Q&A session and sustained questioning, the BOD were asked to disclose the tests they were going to utilise, when asked whether they were going to use Casanova autoantibodies test, they answered yes. When then asked who’s the manufacturer and was it ThermoFisher, they refused to disclose the manufacturer due to confidentiality and added the test was not generally/commercially available yet.

Appears to be a perfect marriage for all parties concerned.

Quote from P.Monk post AGM:

“Their absolute focus is hitting their primary endpoints on these upcoming trials and doing everything they can to target the right patients”.

Asked whether dexamethasone administered patients would be excluded., he stated “it wouldn’t make a difference if they were or not. Dexa only inhibits the production of interferon - it doesn’t interact with administered interferon”.

Went on to say, “they still saw signal strength from the Sprinter trial and this wouldn’t have been the case if dexa was an issue”.

Remember SARS-Cov2 and COPD patents applications from 20/21 both still contain the use of/combination with corticosteroids.

Gunto2022

There’s been a consistent effort to orchestrate support for low ball offers, the thread title is telling.

Spacman

Perhaps you missed my point on ‘real value’

“You know very well the ILI granted patent asset only becomes of real value when SNG001 obtains authorisation for use”.

Spacman

You know very well the ILI granted patent asset only becomes of real value when SNG001 obtains authorisation for use.

The other patent applications are still in the process of examination by the relevant jurisdictions.

Doc.Daneeka

I see nothing untoward in RM’s statement regarding ‘open label’, if it happens it will run alongside their planned Phase2 trials.

Another comment made at the AGM:

“Universal - 300 odd samples already taken and in freezer. These will be studied and used for analysis. Not waiting for any more patients/samples”

Doc.Daneeka

I can confirm that it was stated during the AGM proceedings that some trial participants are likely to be ‘open label’.

RM stated that these patients will be known to physicians treating them as they turn up regularly with the same respiratory problems.

Also during the after-chat, P.Monk said the Phase2 trials are likely to be U.K and U.S. based trials.

Monteacute,

Many lessons and insights were gained from the nature of the un-targeted Sprinter trial, perhaps a couple of hundred extra patients would have got us over the line, unfortunately that increase in numbers may have not been agreeable to the regulatory bodies.

Imo the targeted nature of the planned company sponsored Phase2 trials utilising the pre-testing they intend to employ will prove beneficial for a successful route to Phase3 trials.

Monteacute

Comment made by P.Monk during post AGM after-chat following questions from an attendee I was with:

“I asked whether dexamethasone administered patients would be excluded. He said it wouldn’t make a difference if they were or not. Dexa only inhibits the production of interferon - it doesn’t interact with administered interferon.”

Apologies for previous post, wrong Tom Wilkinson I believe.

Professor Tom Wilkinson AI Horizon involvement:

https://futurescot.com/a-revolution-on-the-horizon/amp/

Doc.Daneeka

AI at Southampton may well have benefits for Universal and Synairgen’s upcoming phase2 trials.

https://www.it-innovation.soton.ac.uk/spotlights/mysmartcopd

Tommy,

Apparently they’ll be from the allocation originally awarded to the departing CFO, some of which will have lapsed on his departure as he will no longer be able to contribute to the company’s performance.

Options RNS 22nd June 23:

Following the options grant there are 18,119,156 options in issue.

Options RNS 15th November 23;

Following the options grant there are 18,940,446 options in issue.

That difference equates to 821,290 options in issue.

To enable the new 1,500,000 issue, would in all likelihood suggest they have held some share options already announced (not issued) in abeyance from previous share option issues.

Doc_Daneeka

Regarding SOC and Sprinter, the following comment from Philip Monk was made to an attendee I know during the post AGM chat:

“I asked whether dexamethasone administered patients would be excluded. He said it wouldn’t make a difference if they were or not. Dexa only inhibits the production of interferon - it doesn’t interact with administered interferon.

He knew where I was coming from but said they still saw signal strength from sprinter trial and this wouldn’t have been there if dexa was an issue.”

ToomyD_19

Just add to my previous post,

It was stated that the U.S remains their target market.